Department of Psychiatry, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Psychiatry Res. 2012 Dec 30;200(2-3):544-9. doi: 10.1016/j.psychres.2012.07.012. Epub 2012 Aug 1.
We investigated the effects of the administration of dehydroepiandrosterone (DHEA) on weight, bone metabolism, bone density and clinical mood symptoms in outpatient Anorexia Nervosa (AN) patients. AN patients (n=26) were double-blindly randomized to receive DHEA (100mg) or placebo for 6 months. Outcome measures were bone mineral density (BMD) and bone mineral content (BMC) measured by dual energy X-ray absorptiometry (DXA) and metabolism indexes, steroid hormones, and mood and eating disorder symptoms measured at baseline and at the 3 and 6 months follow-up visits. Mood and eating disorder symptoms were assessed monthly by the Beck Depression Inventory, Eating Disorder Inventory and Clinical Global Improvement Scales. No treatment or treatment by time interaction was observed for any bone density measures. Deoxypiridinolyne (DPD) was positively correlated with weight (P=0.02). An increase in body mass index (BMI) in the DHEA group was significantly higher at 4 months compared to the control group (P=0.05). Improvement of mood was significantly correlated with weight only in the DHEA group. Despite a significant decrease in DPD, no improvement in bone mineral density was detected. However, patients treated with DHEA benefited from a significant increase in BMI, which was positively correlated with improvement in mood.
我们研究了脱氢表雄酮（DHEA）给药对门诊神经性厌食症（AN）患者体重、骨代谢、骨密度和临床情绪症状的影响。将 26 名 AN 患者随机双盲分为 DHEA（100mg）组或安慰剂组，治疗 6 个月。采用双能 X 线吸收法（DXA）测量骨矿物质密度（BMD）和骨矿物质含量（BMC），代谢指标、类固醇激素以及基线和 3、6 个月随访时的情绪和饮食障碍症状。每月采用贝克抑郁量表、饮食障碍量表和临床总体印象量表评估情绪和饮食障碍症状。任何骨密度测量均未观察到治疗或治疗与时间的相互作用。脱氧吡啶啉（DPD）与体重呈正相关（P=0.02）。与对照组相比，DHEA 组的体重指数（BMI）在 4 个月时显著增加（P=0.05）。DHEA 组的情绪改善与体重显著相关。尽管 DPD 显著下降，但骨密度无改善。然而，DHEA 治疗的患者 BMI 显著增加，且与情绪改善呈正相关。
